Wednesday, October 14, 2026

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SOLS $9.7BSBUX $109B

Yet Another Value Podcast Oct 14 87 clicks

Oct 14 NVDA $5.2T

An Interview with Nvidia’s Ian Buck on Why GPUs Keep Winning

Key Context by Tae Kim 5 clicks

Oct 14 COHR $52B

Coherent | Management Call

P Equity Research 19 clicks

From X

@RagingVentures Oct 14 2 clicks

Raging Capital Ventures on X

@orrdavid @merrillmatter To be fair, I asked you *a lot* of questions - $SPCX was far from the hardest! In response, you were fully transparent and didn’t dodge any of my questions. You were great. I can’t wait to share the full cleaned up transcript of our discussion, likely in early November.

@LaughingH20Cap Oct 14 5 clicks

Laughing Water Capital on X

@bufetmastermind @secretlyaninja @mbamcnulty maybe i don't. I'd appreciate if you could explain. they had said 50% FCF margin on $1B in sales. $LQDA is still going to get to $1B in sales. Its just going to take longer. Tell me why 50% FCF margins are not in play. Bonus points if you can tell why they won't reduce costs

@HaydenCapital Oct 14 1 click

Fred Liu on X

Is Tiktok Shop slowing? J&T Express just reported SE Asia parcel volumes, and are flat for the year at ~31M per day for the last few qtrs. They're guiding to 50-55% full year growth, implying Q4 holiday season only ramps to 33-37M parcels. Evidence Shopee's VIP & logistics investments are working? $SE $1519.HK

@hkuppy Oct 14 1 click

Kuppy on X

I’m sure that $CRWV is money good on funding its gazillions of chip purchase orders, as long as someone funds $CRWV…🤭🤭 https://t.co/TOnS6iGurC

@gnoble79 Oct 14 8 clicks

George Noble on X

Keith, you are a total POS. You belong in jail for securities fraud. I own you. You laughed at me first shorting $OOEN at 8. You are such a pathetic, odious pile of garbage. So pathetic. The entire world is laughing at you. Thanks for playing. $OPEN @rabois @ericjackson @APompliano @

@BrokenMoats Oct 14 4 clicks

Broken Moats on X

Hottest trade in the past month.....retail stocks Seems odd with rates and oil and diesel moves over the same time frame. And these are not bounces from being oversold these are double digit moves in most cases to new highs while dpz struggled on their print this week, stocks like DKS collapsed around the time this trade started. Bifurcation in retail in recent weeks that seems to be favoring low quality. Something to watch for a reversal soon $KSS $FIGS $URBN $SHOP

@BlueDuckCap Oct 14 5 clicks

BDC on X

It's been 189 days since @evanspiegel had a confirmed sale. The longest sales void ever, per what we can discern from filings. He's in a blackout window now. If the sales do not resume post Q3 window opening then that would seem bullish. We would love an insider buy, too. Evan buys stock here we would think $SNAP is +10% on that day. At least. Not advice. Just pointing out the cadence of form 4's and lack of historical insider buying.

@ACapitalLP Oct 14 3 clicks

A Capital on X

$KYIV https://t.co/bGd6IJ4Xl0

My 2028 numbers

ASML’s €11.7 billion quarter benefited from €3.3 billion in installed-base sales and operating leverage, while the MATCH Act threatens…

ASML $631B

Best Anchor Stocks Oct 14 26 clicks

Visa: Unpacking The 7 Powers And Forward Valuation Ahead Of Q4 Earnings

Visa’s network economics support long-term compounding, but a 1.7–1.8 forward PEG and risks to high-margin payment revenues limit near-term…

V $750B

C Jessen Oct 14 36 clicks

Deep Dive: Applied Materials ($AMAT)

Applied Materials leads wafer-fab deposition and ranks third in etch, positioning it for tougher 3D chip manufacturing as investors weigh a…

AMAT $359B

Rebound Capital Oct 14 30 clicks

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…

TEVA $48B

Equity Eagle Oct 14 8 clicks

Research Roundup Vol. LVI

Howmet Aerospace is framed as a beneficiary of turbine and aircraft-engine demand, while J.B.

HWM $88BJBHT $22B

Monte Independent Investment Research Oct 14 14 clicks

Lennar: The Misstep Is Temporary, the Operating Machine Is Not

Lennar cut build times to 116 days and adopted an asset-light land model, while gross margin fell to 15.8% from 27.5% as land costs rose.

LEN $17B

Latticework by MOI Global Oct 14 16 clicks

Lennar, Part One: The Story

Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…

LEN $17B

Latticework by MOI Global Oct 14 15 clicks

Lennar, Part Two: The Deep Dive

Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.

LEN $17B

Latticework by MOI Global Oct 14 13 clicks

ASML Q3 FY12/26 Earnings Review

ASML reported Q3 sales of €11.7 billion, up 55% year over year, and guided Q4 sales to €14.2 billion to €15.2 billion amid capacity…

ASML $631B

Cestrian Capital Research Oct 14 9 clicks

Eaton: Strong Backlog And Margin Recovery Support The Buy Case

Eaton’s backlog, data-center, grid and aerospace demand, plus a 450–500 bp H2 2026 Electrical Americas margin recovery, support the growth…

ETN $156B

Value Capital Research Oct 14 7 clicks

ASTS · short

Ast Spacemobile INC

AST SpaceMobile is priced for a 2026 commercial launch despite no identified path to manufacture or launch its satellite deployment target.

ASTS $16B

Value Investors Club Apr 29 10 clicks

Adobe Stock Breakdown (Five Minute Money)

Adobe trades at 14x free cash flow after a 60% decline despite growth, with AI, its business-model transition and creative-software…

ADBE $98B

Speedwell Memos Feb 12

Ferrari Exploratory Report

Ferrari sells about 13,000 vehicles annually, generating €7 billion of revenue and 28% operating margins; its shares trade at 32 times…

RACE $70B

Speedwell Memos Feb 10 1 click

FDA vs. HIMS: Why the Oral “Wegovy Copy” Crackdown Changes the GLP-1 Game

FDA’s crackdown on HIMS’s $49 compounded oral Wegovy copy reshapes GLP-1 competition after Novo Nordisk forecast 2026 sales and profit…

NVO $172BHIMS $6.6B

Modern Value Investing Feb 8

Evolution: 4Q25 Business Update

Evolution's fourth-quarter revenue fell 4% as Asia cyber disruption and European channelization outweighed U.S.

EVVTY $15B

Speedwell Memos Feb 6 1 click

Adobe Inc (ADBE): slowly, then all at once

Adobe’s sub-20x forward GAAP P/E reflects AI disruption fears, with the investment case hinging on whether Digital Media’s creative…

ADBE $98B

Bristlemoon Capital Feb 6

2026: Radio silence, software setbacks and more from me in 2026

RELX and Sage have fallen 46% and 35% as markets label them AI losers, creating potential value opportunities alongside risks of genuine…

GOOGL $4.3T

The Curious Compounder Feb 5

My Biggest Position: A Monopoly Priced for Failure

A former value-investor darling, down 50%, pairs a monopoly with a recurring-revenue razor-and-blade business; debt paydown, margin…

PBI $2.3B

Treasure Hunting Feb 5 3 clicks

Mispriced Kalshi Contract: Snapchat Family Center

Kalshi’s 87% odds of “Family Center” on Snap’s earnings call far exceed its 2.9% historical mention rate and a 15–20% street-adjusted…

SNAP $10B

First Strike Research Feb 2

CrowdStrike: A Glass DeathStar during SaaSmageddon | Short Thesis

CrowdStrike faces a renewal cliff after its July 2024 outage, with Microsoft Defender bundling, litigation, SEC and DOJ scrutiny, and a…

CRWD $233B

First Strike Research Feb 1

Wednesday, October 14, 2026

Raging Capital Ventures on X

Laughing Water Capital on X

Fred Liu on X

Kuppy on X

George Noble on X

Broken Moats on X

BDC on X

A Capital on X

Investor Letters

Publications we follow

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 238

X accounts we follow

Investor letters we follow

Sectors